ArticleJournal of advanced research2026
Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Histone deacetylases in cancer metabolic reprogramming.Experimental & molecular medicine · 2026Review
- Metabolic Messengers: Extracellular Vesicles as Central Mediators of Metabolic Reprogramming in Renal Cell Cancer.Biomedicines · 2026Review
- Patient-Derived Organoids as a Platform to Decipher and Overcome Radioresistance: From the Tumor Microenvironment to Radiosensitizer Discovery.Current oncology (Toronto, Ont.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRenal cell carcinoma (RCC) is a common cancer that seriously threatens human health. Advanced RCC is characterized by poor responsiveness to radiotherapy and chemotherapy, with targeted therapy and immunotherapy currently serving as the primary treatment modalities. However, the issue of therapeutic resistance remains a major challenge, necessitating the identification of novel therapeutic targets. Emerging evidence indicates that dysregulated lipid metabolism is a hallmark of RCC and represents a potential therapeutic target for this disease.
objectivesTo elucidate the mechanisms underlying abnormal lipid metabolism in RCC and identify suitable targets for its treatment.
methodsBioinformatics screening and analysis were performed to identify hub gene. qRT-PCR, western blot, immunohistochemistry (IHC), and methylation-specific PCR (MSP) were employed to verify the target gene expression. CCK-8 assays, transwell assays, comprehensive targeted lipidomics, co-immunoprecipitation (Co-IP), and immunofluorescence were used to investigate biological functions and mechanisms. The in vivo functions, mechanisms, and translational potential of the target gene were further validated using 3D cell culture systems, organoid models, and animal models.
resultsIn this study, we identify Lysine Acetyltransferase 2B (KAT2B) as a lipid-related biomarker in RCC, demonstrating that its low expression is associated with poor patient prognosis. Promoter hypermethylation contributes to the reduced expression of KAT2B in RCC. Mechanistically, KAT2B acetylates HDAC5 at lysine 726 (K726), facilitating its interaction with Exportin1 and subsequent nuclear export. This process disrupts the nuclear HDAC5-LSD1 complex, enhances histone methylation, and suppresses the expression of fatty acid synthase (FASN). The loss of KAT2B leads to elevated FASN expression and lipid accumulation, driving RCC progression. Notably, pharmacological inhibition of FASN mitigates these effects.
conclusionOur findings reveal that KAT2B suppresses de novo lipogenesis by interfering with HDAC5-LSD1 complex assembly, and highlight the potential of FASN inhibitors as a therapeutic strategy for RCC patients with low KAT2B expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.